In contrast, the predominant MSS CRC exhibit minimal or virtually no response to monotherapy with PD‐1/PD‐L1 ICIs [7], significantly constraining the clinical application of immune checkpoint blockade therapy in CRC. Here, PDCD1 is linked to colorectal carcinoma.